在严重喘中对生物治疗的有效性评估
Daniel Laorden1, Javier Domínguez-Ortega2, David Romero1
1Department of Pneumology, Hospital La Paz, Universidad Autónoma de Madrid, IdiPAZ, and CIBER of Respiratory Diseases, 28046 Madrid, Spain.
Journal of clinical medicine
|January 25, 2025
概括
生物疗法为严重喘患者提供了新的希望. 使用临床标志物和生物标志物 (如血液中乙氨基和FeNO) 评估治疗反应是个性化护理和改善结果的关键.
科学领域:
- 肺病学和呼吸系统医学
- 免疫学和过敏学
- 药理学和治疗学 药理学和治疗学
背景情况:
- 严重的,不受控制的喘在全球范围内影响着大量患者,尽管有现有治疗方法,但这仍构成了临床挑战.
- 生物疗法通过向特定的炎症途径,改变了严重喘的治疗方法.
- 评估治疗疗效需要标准化的标准和个性化的方法.
研究的目的:
- 审查严重喘生物治疗的疗效和反应标准.
- 突出临床,功能和炎症标志物在评估生物治疗有效性的作用.
- 讨论个性化医疗策略,包括预测因素和治疗调整.
主要方法:
- 对严重喘中的生物疗法进行全面的文献综述.
- 对临床,功能和炎症标志物的分析,以评估治疗反应.
- 检查现实世界的数据,预测因素和定量工具 (例如FEOS评分,EXACTO问卷).
主要成果:
- 关键反应指标包括症状控制,减轻恶化,改善肺功能和减少口服皮质类固醇使用.
- 生物标志物,如血中乙氨基基和分数排气的氧化 (FeNO),对于指导治疗至关重要.
- 患者特异性因素,包括治疗前的肺功能和并发症 (肥胖,鼻炎),影响治疗反应.
结论:
- 个性化治疗策略,由生物标志物和预测因素提供信息,对于优化严重喘的生物疗法至关重要.
- 持续的重新评估和潜在的治疗修改是必要的,以达到不理想的反应.
- 根据个体患者的个人形状和表型量身定制生物治疗,可以改善患者的治疗结果和生活质量.
相关概念视频
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
231
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
231
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
234
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
234
01:19Antiasthma Drugs: Leukotriene Modifiers
239
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
239
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
216
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
216
01:20Asthma: Pathogenesis and Management
343
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
343